Zepbound vs Mounjaro: what's the difference?

Zepbound and Mounjaro are the same molecule sold under two different names. Both contain tirzepatide, made by Eli Lilly. The only real difference is what the FDA says each one is for: Mounjaro treats type 2 diabetes, and Zepbound treats obesity. That distinction matters more than you’d think, because it changes what your insurance will cover and what you’ll pay out of pocket.

If you’re comparing weight loss medications, the Zepbound vs Mounjaro question is really about insurance and indication, not pharmacology.

Quick comparison table

Feature	Zepbound	Mounjaro
Active ingredient	Tirzepatide	Tirzepatide
Drug class	Dual GIP/GLP-1 receptor agonist	Dual GIP/GLP-1 receptor agonist
FDA-approved for	Chronic weight management, obstructive sleep apnea	Type 2 diabetes
Manufacturer	Eli Lilly	Eli Lilly
Dosing schedule	Once weekly injection	Once weekly injection
Available doses	2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg	2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg
Average weight loss	16-22.5% of body weight (SURMOUNT-1)	16-22.5% (same drug, same data)
Monthly cost (retail)	~$1,080	~$1,112
Self-pay options	$499/month (Lilly direct)	Limited savings programs
Insurance coverage	Weight loss coverage rare	Often covered for diabetes

Key differences

Zepbound and Mounjaro are pharmacologically identical. Same active ingredient, same dose options, same manufacturer, same mechanism. The split exists purely for regulatory and insurance purposes.

Mounjaro received FDA approval for type 2 diabetes in May 2022. Zepbound followed in November 2023 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition [1]. In 2024, the FDA also approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity [2].

The practical difference comes down to your diagnosis and your insurance plan.

How tirzepatide works

Tirzepatide is a dual GIP and GLP-1 receptor agonist. That means it activates two gut hormone receptors instead of one, which separates it from semaglutide-based medications like Ozempic and Wegovy that only target GLP-1.

GLP-1 activation slows gastric emptying, reduces appetite, and improves insulin sensitivity. GIP activation adds to the metabolic effect by enhancing fat metabolism and further improving insulin response. The combination produces stronger weight loss results than GLP-1 alone.

Both Zepbound and Mounjaro start at 2.5 mg weekly and can be titrated up to 15 mg based on tolerability and response. The titration schedule is the same for both.

Weight loss data

Because they’re the same drug, the clinical trial data applies to both.

The SURMOUNT-1 trial studied tirzepatide in 2,539 adults with obesity or overweight (without diabetes). At 72 weeks, participants lost an average of 16.0% of body weight on the 5 mg dose, 21.4% on 10 mg, and 22.5% on 15 mg, compared to 3.1% with placebo. About nine out of ten participants taking tirzepatide lost weight [3].

For context, semaglutide 2.4 mg (Wegovy) produced 14.9% weight loss at 68 weeks in the STEP 1 trial [4]. Tirzepatide’s dual-agonist approach appears to produce greater weight reduction than single-agonist GLP-1 drugs.

The SURPASS trials studied tirzepatide in patients with type 2 diabetes specifically. Weight loss in that population averaged 12-15%, which is lower than in the obesity-only population but still significant compared to other diabetes medications [5].

Side effects

Since the active ingredient is identical, side effects are the same for both medications.

The most common adverse events from SURMOUNT-1 [3]:

• Nausea: 24-33% (depending on dose)
• Diarrhea: 18-23%
• Vomiting: 9-13%
• Constipation: 11-17%
• Decreased appetite: 9-12%

Most gastrointestinal side effects occur during dose escalation and tend to decrease over time. Serious adverse events were reported in about 6-7% of participants, comparable to placebo.

Tirzepatide carries a boxed warning about thyroid C-cell tumors based on animal studies. It’s contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. The same warning applies to both Zepbound and Mounjaro.

Injection site reactions occurred in about 3-5% of participants in the SURMOUNT trials. These were generally mild: redness, itching, or a small bump that resolved within a few days. Rotating injection sites helps minimize this.

If you’re weighing side effects across different weight loss options, both versions of tirzepatide have a similar safety profile to other GLP-1 medications. For patients concerned about GI side effects specifically, slow dose titration (staying at each dose level for at least 4 weeks) reduces the severity considerably.

Cost comparison

This is where the Zepbound vs Mounjaro distinction actually matters.

Mounjaro pricing:

• Retail list price: approximately $1,112 per month [6]
• With commercial insurance (for diabetes): potentially as low as $25/month with savings card
• Without insurance: over $12,000 per year at list price

Zepbound pricing:

• Retail list price: approximately $1,080 per month
• Eli Lilly self-pay program: $499/month without insurance [7]
• With commercial insurance (if covered): potentially as low as $25/month

The catch: most insurance plans cover Mounjaro for type 2 diabetes, but very few cover Zepbound for weight loss. Even plans that cover Mounjaro for diabetes may deny the same molecule when prescribed as Zepbound for obesity.

Some prescribers work around this by prescribing Mounjaro off-label for weight loss in patients who also have insulin resistance or prediabetes. Whether that’s an option depends on your clinical situation and your insurance plan’s formulary rules.

The affordable alternative: Compounded tirzepatide from licensed 503A and 503B pharmacies can cost significantly less than either brand-name version. Through telehealth clinics, compounded options typically run $300-$500 per month depending on dose.

Check if you qualify for affordable tirzepatide through our program →

Insurance coverage: the real deciding factor

For most patients, the Zepbound vs Mounjaro decision comes down to what your plan will pay for.

Employer-sponsored plans increasingly cover Mounjaro for type 2 diabetes. If you have diabetes and your A1C is above 7%, getting Mounjaro approved is usually straightforward. The Eli Lilly savings card can bring the copay down to $25/month.

Weight loss coverage is a different story. Only about 25-30% of commercial insurance plans cover anti-obesity medications like Zepbound. Medicare Part D doesn’t cover weight loss drugs at all, though there’s ongoing legislative effort to change that. Some state Medicaid programs have added coverage, but it varies widely.

If your plan denies Zepbound, your prescriber can sometimes appeal based on weight-related comorbidities (sleep apnea, hypertension, prediabetes). The 2024 FDA approval of Zepbound for obstructive sleep apnea opened a new pathway for patients with that diagnosis.

For patients without any coverage, compounded tirzepatide at $300-$500/month is often the most practical path. You get the same molecule without the insurance fight.

Who should choose which

Choose Mounjaro if:

• You have type 2 diabetes and your insurance covers it
• Your doctor has prescribed it for blood sugar management
• You’ll benefit from both glycemic control and weight loss

Choose Zepbound if:

• Your primary goal is weight management and you don’t have diabetes
• Your insurance specifically covers anti-obesity medications
• You want to use the Eli Lilly $499/month self-pay option

Consider compounded tirzepatide if:

• You don’t have insurance coverage for either brand
• The $499-$1,100 monthly price point is too high
• You want the same active ingredient at a lower cost through a licensed telehealth provider

FAQ

Are Zepbound and Mounjaro the exact same drug?▼

Yes. Both contain tirzepatide, manufactured by Eli Lilly. The formulation, dose options, and delivery method (once-weekly subcutaneous injection) are identical. The only difference is the FDA-approved indication: Mounjaro for type 2 diabetes, Zepbound for chronic weight management and obstructive sleep apnea.

Can I switch from Mounjaro to Zepbound?▼

You can, but it requires a new prescription. Your doctor would prescribe Zepbound at the same dose you were taking of Mounjaro. The main reason people switch is if their insurance changes coverage or if they no longer have a diabetes diagnosis requiring Mounjaro. There’s no medical reason to switch since the medication is identical.

Is Zepbound better than Ozempic for weight loss?▼

Clinical trials suggest tirzepatide (Zepbound) produces more weight loss than semaglutide (Ozempic/Wegovy). The SURMOUNT-1 trial showed 22.5% weight loss at the highest dose of tirzepatide, compared to 14.9% with semaglutide in the STEP 1 trial [3][4]. However, these were separate trials, not a head-to-head comparison. Individual results vary. For a deeper breakdown, see our semaglutide vs tirzepatide comparison.

Does insurance cover Zepbound or Mounjaro for weight loss?▼

Insurance coverage for weight loss remains limited. Most plans cover Mounjaro only for type 2 diabetes. Zepbound coverage for obesity is growing but still uncommon, particularly among employer-sponsored plans. Medicare Part D does not cover anti-obesity medications at all. Check with your specific plan.

How much does compounded tirzepatide cost compared to Zepbound?▼

Compounded tirzepatide from licensed pharmacies typically costs $300-$500 per month, compared to Zepbound’s $499-$1,080 monthly cost. Compounded versions are available through telehealth prescribers and use the same active ingredient prepared by FDA-regulated compounding pharmacies.

Can I get a generic version of Mounjaro or Zepbound?▼

No generic tirzepatide exists as of 2026. Eli Lilly holds the patent, and generic competition isn’t expected for several years. Compounded tirzepatide is the closest alternative to a generic option currently available. For a broader look at what “generic” options exist in the GLP-1 space, see our generic Ozempic guide.

How long does it take to see results on Zepbound or Mounjaro?▼

Most patients notice appetite suppression within the first 2-4 weeks on the starting dose of 2.5 mg. Measurable weight loss typically begins by weeks 4-8 as the dose is titrated upward. In SURMOUNT-1, the most rapid weight loss occurred between weeks 12-36 at the higher doses. The full effect takes 6-9 months to materialize.

Find out if you qualify for affordable GLP-1 treatment →

References

1. FDA. FDA approves new medication for chronic weight management. November 2023.
2. FDA. FDA approves Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. December 2024.
3. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
4. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
5. Frías JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519
6. GoodRx. How much is Mounjaro with and without insurance? Updated 2025.
7. Eli Lilly. Zepbound cost information. pricinginfo.lilly.com/zepbound. Accessed April 2026.